Fondaparinux in acute coronary syndromes
Fondaparinux has a number of advantages over both UFH and LMWH. 1,3,17 It is manufactured entirely by synthetic chemical means, rather than from animal extracts. It does not interact with platelets or bind to PF4, and it does not promote HIT. The antithrombin-binding sequence of fondaparinux is the shortest fragment able to catalyze antithrombin-mediated factor Xa inhibition. The anti-factor Xa specificity of the pentasaccharide allows a more predictable anticoagulant dose and effect without necessitating safety monitoring of coagulation parameters.